Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials

Drug Discov Today. 2015 Dec;20(12):1422-8. doi: 10.1016/j.drudis.2015.08.005. Epub 2015 Aug 28.


Implementing a center-wide precision medicine strategy at a major cancer center is a true multidisciplinary effort and requires comprehensive alignment of a broad screening strategy with a clinical research enterprise that can use these data to accelerate development of new treatments. Here, we describe the genomic screening approach at Memorial Sloan Kettering Cancer Center, a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology designated MSK-IMPACT, and how it enables and supports a large clinical trial portfolio enriched for multi-histology, biomarker-selected, 'basket' studies of targeted therapies.

MeSH terms

  • Clinical Trials as Topic / methods
  • High-Throughput Nucleotide Sequencing / methods
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / genetics*
  • Precision Medicine / methods